The estimated Net Worth of Peter Mueller is at least $2.84 Million dollars as of 23 August 2019. Peter Mueller owns over 1,554 units of BioXcel Therapeutics Inc stock worth over $92,576 and over the last 21 years he sold BTAI stock worth over $2,539,962. In addition, he makes $202,603 as Independent Chairman of the Board at BioXcel Therapeutics Inc.
Peter has made over 54 trades of the BioXcel Therapeutics Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 1,554 units of BTAI stock worth $14,514 on 23 August 2019.
The largest trade he's ever made was exercising 122,300 units of BioXcel Therapeutics Inc stock on 2 July 2013 worth over $3,766,840. On average, Peter trades about 5,559 units every 49 days since 2003. As of 23 August 2019 he still owns at least 168,320 units of BioXcel Therapeutics Inc stock.
You can see the complete history of Peter Mueller stock trades at the bottom of the page.
Dr. Peter Mueller Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Mueller is currently the President of the Mueller Health Foundation, a private foundation tackling globally lethal infectious diseases such as tuberculosis by addressing latency and the ever growing challenges of antimicrobial resistance. From 2014 to 2016, he was President of R&D and Chief Scientific Officer of Axcella Health, a biotechnology company. From 2003 to 2014, Dr. Mueller served as Executive Vice President Global Research and Development & Chief Scientific Officer for Vertex Pharmaceuticals, Incorporated, a biotechnology company. He was involved in the development of Incivek (2011), Kalydeco (2012), and Orkambi (2014). Prior to his tenure at Vertex, he served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. overseeing global research programs (immunology, inflammation, cardiovascular diseases and gene therapy) and the development of all drug candidates of the company’s worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He was involved in the development of Spiriva, Combivent, Atrovent and Viramune. Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University. He is a member of various scientific and political societies and currently serves on the Board of the US-India Chamber of Commerce Biotech. He also services as chairman of the Scientific Advisory Board of BioXcel and is an advisor to the University Iowa (CBB). Mueller’s extensive experience in the life sciences industry as a scientist and executive qualifies him to serve as a director of our Company.
As the Independent Chairman of the Board of BioXcel Therapeutics Inc, the total compensation of Peter Mueller at BioXcel Therapeutics Inc is $202,603. There are 5 executives at BioXcel Therapeutics Inc getting paid more, with Vimal Mehta having the highest compensation of $1,968,930.
Peter Mueller is 63, he's been the Independent Chairman of the Board of BioXcel Therapeutics Inc since 2017. There are 3 older and 10 younger executives at BioXcel Therapeutics Inc. The oldest executive at BioXcel Therapeutics Inc is Dr. Frank D. Yocca Ph.D., 65, who is the Sr. VP & Chief Scientific Officer.
Peter's mailing address filed with the SEC is C/O BIOXCEL THERAPEUTICS, INC.,, 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511.
Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over $63,244,788 worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth $321,105 . The most active insiders traders include Vimal Bio Xcel Holdings, In..., Vimal Mehta, and Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $29,814. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth $413.
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include: